NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 In this analysis of the previously reported JUPITER study, rosuvastatin 20mg daily compared with placebo reduced the risk of symptomatic VTE in people with few elevated […]
Category Archives: Cardiovascular disease
NPC Archive Item: Rosuvastatin has no CV benefits in patients undergoing haemodialysis
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 The AURORA study found rosuvastatin had no cardiovascular mortality or morbidity benefits in patients with end-stage renal disease undergoing haemodialysis. Action Patients with chronic kidney disease […]
NPC Archive Item: Prasugrel▼ (Efient®) in patients with STEMI
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th March 2009 A pre-specified subgroup analysis of the TRITON-TIMI 38 trial suggests that prasugrel ▼ may be more effective than clopidogrel in those with STEMI ACS undergoing PCI. Major […]
NPC Archive Item: Dronedarone in atrial fibrillation – does ATHENA provide the answers?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5th March 2009 In the ATHENA trial of 4,628 patients with atrial fibrillation (AF) or flutter, dronedarone was more effective than placebo in reducing cardiovascular (CV) hospital admissions or […]
NPC Archive Item: FDA investigates possible safety concerns over clopidogrel
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th February 2009 The US Food and Drug Administration has published information about an ongoing safety review of clopidogrel. This follows reports suggesting it is less effective in some […]
NPC Archive Item: Fish oils don’t reduce arrhythmias or all cause mortality, but may reduce deaths from cardiac causes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A recent systematic review found no benefit for fish oil supplements in reducing the risk of sudden cardiac death or all cause mortality. There was a reduction in death […]
NPC Archive Item: MeReC Bulletin on lipid modification now published
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. This MeReC Bulletin summarises the NICE guidance on lipid modification and addresses some important supplementary clinical questions. The most recent MeReC Bulletin: Lipid-modifying treatment (Vol. 19, No. 3) is […]
NPC Archive Item: Meta-analysis demonstrates statins benefit on total mortality in primary prevention
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A recent systematic review of statins for primary prevention reports that statins significantly reduced the risk of major cardiovascular events, mortality from cardiovascular disease and total mortality. Action: This […]
NPC Archive Item: Is one beta-blocker better than another in heart failure?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A large cohort study found that among patients admitted with heart failure, the adjusted risk of death in the following 12 months was similar among patients taking atenolol and […]
NPC Archive Item: Rivaroxaban (Xarelto®▼) reduces symptomatic VTE and death more than enoxaparin in patients undergoing hip or knee replacement
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Results from a pre-specified pooled analysis of the four, double-blind, double-dummy phase 3 (RECORD) studies have been presented as a conference abstract at the 50th Meeting of the American […]